|
1
|
Karati D and Kumar D: A comprehensive
review on targeted cancer therapy: New face of treatment approach.
Curr Pharm Des. 29:3282–3294. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumari S, Advani D, Sharma S, Ambasta RK
and Kumar P: Combinatorial therapy in tumor microenvironment: Where
do we stand? Biochim Biophys Acta Rev Cancer. 1876:188585–188597.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pandit K, Garg C, Bhat AH, Bhardwaj R and
Kaur S: Harnessing dietary phytochemicals to modulate signaling
pathways in cancer chemoprevention-A review. Phytother Res.
39:3271–3299. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Doghish AS, Zaki MB, Hatawsh A, Elfar N,
Alhamshry NAA, Abd-Elmawla MA, Aborehab NM, Radwan AF, Moussa R,
Mageed SSA, et al: Alternative medicines in oncology: A focus on
natural products against gastric cancer. Naunyn Schmiedebergs Arch
Pharmacol. 398:13065–13086. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Y, Li Q, Huang Y, Yang Z, Li G, Sun X,
Gu X, Qiao Y, Wu Q, Xie T and Sui X: Natural products for enhancing
the sensitivity or decreasing the adverse effects of anticancer
drugs through regulating the redox balance. Chin Med. 19:1102024.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar M, Kaur V, Kumar S and Kaur S:
Phytoconstituents as apoptosis inducing agents: Strategy to combat
cancer. Cytotechnology. 68:531–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farzaei MH, Bahramsoltani R and Rahimi R:
Phytochemicals as adjunctive with conventional anticancer
therapies. Curr Pharm Des. 22:4201–4218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishino H, Tokuda H, Satomi Y, Masuda M,
Osaka Y, Yogosawa S, Wada S, Mou XY, Takayasu J, Murakoshi M, et
al: Cancer prevention by antioxidants. Biofactors. 22:57–61. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choudhari AS, Mandave PC, Deshpande M,
Ranjekar P and Prakash O: Phytochemicals in cancer treatment: From
preclinical studies to clinical practice. Front Pharmacol.
10:16142020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizuno H, Yoshikawa H and Usuki T:
Extraction of Nobiletin and Tangeretin From Peels of Shekwasha and
Ponkan Using [C2mim][(MeO)(H)PO2] and Centrifugation. Nat Prod
Commun. 14:1–6. 2019.PubMed/NCBI
|
|
11
|
Arshad R, Masood S, Sharif HR, Goksen G,
Xu B and Faisal Manzoor M: New Insights into Health-Promoting
Effects of Nobiletin from Citrus Fruits. Food Rev Int.
40:1276–1295. 2024. View Article : Google Scholar
|
|
12
|
Yakıncı ÖF, Emerce E, Gürbüz P, Demi̇rel
M, Demi Rel MA, Çeri Başı S and Süntar İ: Cytotoxic effects of
citrus peels on breast tumor: opportunities for waste to raw
material conversion. ACS Omega. 10:16900–16908. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gan R, Liu Y, Li H, Xia Y, Guo H, Geng F,
Zhuang Q, Li H and Wu D: Natural sources, refined extraction,
biosynthesis, metabolism, and bioactivities of dietary
polymethoxyflavones (PMFs). Food Sci Hum Wellness. 13:27–49. 2023.
View Article : Google Scholar
|
|
14
|
Wang JG, Jian WJ, Li Y and Zhang J:
Nobiletin promotes the pyroptosis of breast cancer via regulation
of miR-200b/JAZF1 axis. Kaohsiung J Med Sci. 37:572–582. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goh JXH, Tan LT, Goh JK, Chan KG,
Pusparajah P, Lee LH and Goh BH: Nobiletin and derivatives:
Functional compounds from citrus fruit peel for colon cancer
chemoprevention. Cancers (Basel). 11:8672019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ozkan AD, Sarihan M and Kaleli S:
Evaluation of the effects of nobiletin on toll-like receptor 3
signaling pathways in prostate cancer in vitro. Nutr Cancer.
73:1138–1144. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moazamiyanfar R, Rezaei S, AliAshrafzadeh
H, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E,
Zhaleh M, Taeb S and Najafi M: Nobiletin in cancer therapy;
Mechanisms and therapy perspectives. Curr Pharm Des. 29:1713–1728.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kennel KB, Bozlar M, De Valk AF and Greten
FR: Cancer-associated fibroblasts in inflammation and antitumor
immunity. Clin Cancer Res. 29:1009–1016. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang RH, Lin YK, Xie HK, Li H, Li M and He
D: Exploring the synergistic pharmacological mechanism of Huoxiang
Drink against irritable bowel syndrome by integrated data mining
and network pharmacology. Medicine (Baltimore). 102:e352202023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keshtkar S, Kaviani M, Jabbarpour Z,
Geramizadeh B, Motevaseli E, Nikeghbalian S, Shamsaeefar A,
Motazedian N, Al-Abdullah IH, Ghahremani MH and Azarpira N:
Protective effect of nobiletin on isolated human islets survival
and function against hypoxia and oxidative stress-induced
apoptosis. Sci Rep. 9:117012019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Silva BR and Silva JRV: Mechanisms of
action of non-enzymatic antioxidants to control oxidative stress
during in vitro follicle growth, oocyte maturation, and embryo
development. Anim Reprod Sci. 249:1071862023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Yang Y, Liang H, Liang Y, Xiong
G, Lu F, Yang K, Zou Q, Zhang X, Du G, et al: Nobiletin, as a Novel
PDE4B inhibitor, alleviates asthma symptoms by activating the
cAMP-PKA-CREB signaling pathway. Int J Mol Sci. 25:104062024.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Liu F, Wu Y, Zhu Y, Jiang Y, Wu Q,
Dong Z and Liu K: Inflammation in cancer: Therapeutic opportunities
from new insights. Mol Cancer. 24:512025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang G, Li S, Yuan L, Yang Y and Pan MH:
Effect of nobiletin on the MAPK/NF-κB signaling pathway in the
synovial membrane of rats with arthritis induced by collagen. Food
Funct. 8:4668–4674. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suwal N, Thapa R, Bashyal S, et al:
Targeting oncogenic signaling pathways in lung Cancer: The emerging
role of nobiletin, a flavonoid from citrus peel. Food Bioscience.
69:106887–106896. 2025. View Article : Google Scholar
|
|
26
|
Shewach DS and Kuchta RD: Introduction to
cancer chemotherapeutics. Chem Rev. 109:2859–2861. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen M, Li H, Zheng S, Shen J, Chen Y, Li
Y, Yuan M, Wu J and Sun Q: Nobiletin targets SREBP1/ACLY to induce
autophagy-dependent cell death of gastric cancer cells through
PI3K/Akt/mTOR signaling pathway. Phytomedicine. 128:1553602024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YY, Liang JJ, Wang DL, Chen JB, Cao
JP, Wang Y and Sun CD: Nobiletin as a chemopreventative natural
product against cancer, a comprehensive review. Crit Rev Food Sci
Nutr. 63:6309–6329. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao Z, Zheng J, Wu X, Savinov S, Zhao C
and Xiao H: Heat shock cognate 70 protein is a novel target of
nobiletin and its colonic metabolites in inhibiting colon
carcinogenesis. Food Funct. 15:10447–10458. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei X and Shao X: Nobiletin alleviates
endometriosis via down-regulating NF-κB activity in endometriosis
mouse model. Biosci Rep. 38:BSR201804702018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Da C, Liu Y, Zhan Y, Liu K and Wang R:
Nobiletin inhibits epithelial-mesenchymal transition of human
non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3
signaling pathway. Oncol Rep. 35:2767–2774. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chu CC, Chen SY, Chyau CC and Duh PD:
Antiproliferative effect of sweet orange peel and its bioactive
compounds against human hepatoma cells, in vitro and in vivo. J
Funct Foods. 33:363–375. 2017. View Article : Google Scholar
|
|
33
|
Luo G, Guan X and Zhou L: Apoptotic effect
of citrus fruit extract nobiletin on lung cancer cell line A549 in
vitro and in vivo. Cancer Biol Ther. 7:966–973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma X, Jin S, Zhang Y, Wan L, Zhao Y and
Zhou L: inhibitory effects of nobiletin on hepatocellular carcinoma
in vitro and in vivo. Phytother Res. 28:560–567. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Malik DE, Attar R, Ozbey U, Romero MA,
Yulaevna IM and Purenovic J: Multifunctional role of Nobiletin in
cancer chemoprevention. Cell Mol Biol (Noisy-le-grand). 68:200–207.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang X, Zheng K, Li C, Zhao Y, Li H, Liu
X, Long Y and Yao J: Nobiletin inhibits invasion via inhibiting
AKT/GSK3β/β-catenin signaling pathway in Slug-expressing glioma
cells. Oncol Rep. 37:2847–2856. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li YQ, Fan F, Wang YR, Li LY, Cao YJ, Gu
SM, Liu SS, Zhang Y, Wang J, Tie L, et al: The novel small molecule
BH3 mimetic nobiletin synergizes with vorinostat to induce
apoptosis and autophagy in small cell lung cancer. Biochem
Pharmacol. 216:1158072023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang J, Chang Z, Lu Q, Chen X and Najafi
M: Nobiletin as an inducer of programmed cell death in cancer: a
review. Apoptosis. 27:297–310. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miyamoto S, Yasui Y, Tanaka T, Ohigashi H
and Murakami A: Suppressive effects of nobiletin on hyperleptinemia
and colitis-related colon carcinogenesis in male ICR mice.
Carcinogenesis. 29:1057–1063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Luo G, Zeng Y, Zhu L, Zhang YX and Zhou
LM: Inhibition effect and its mechanism of nobiletin on
proliferation of lung cancer cells. Sichuan Da Xue Xue Bao Yi Xue
Ban. 40:449–453. 2009.(In Chinese). PubMed/NCBI
|
|
41
|
Cheng HL, Hsieh MJ, Yang JS, Lin CW, Lue
KH, Lu KH and Yang SF: Nobiletin inhibits human osteosarcoma cells
metastasis by blocking ERK and JNK-mediated MMPs expression.
Oncotarget. 7:35208–35223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Han SH, Han JH, Chun WJ, Lee SS, Kim HS
and Lee JW: Nobiletin inhibits non-small-cell lung cancer by
inactivating WNT/β-catenin signaling through downregulating
miR-15-5p. Evid Based Complement Alternat Med. 2021:77829632021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mo JS, Han SH, Yun KJ and Chae SC:
MicroRNA 429 regulates the expression of CHMP5 in the inflammatory
colitis and colorectal cancer cells. Inflamm Res. 67:985–996. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Elahi MA, Tariq A, Malik A and Zhra M:
Role of hypoxia-associated long noncoding RNAs in cancer
chemo-therapy resistance. Int J Mol Sci. 26:9362025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao XJ, Liu JW, Zhang QG, Zhang JJ, Xu HT
and Liu HJ: Nobiletin inhibited hypoxia-induced
epithelial-mesenchymal transition of lung cancer cells by
inactivating of Notch-1 signaling and switching on miR-200b.
Pharmazie. 70:256–262. 2015.PubMed/NCBI
|
|
46
|
Zhang Y, Dou H, Li H, He Z and Wu H: The
citrus flavonoid nobiletin inhibits proliferation and induces
apoptosis in human pancreatic cancer cells in vitro. Food Sci
Biotechnol. 23:225–229. 2014. View Article : Google Scholar
|
|
47
|
Jiang YP, Guo H and Wang XB: Nobiletin
(NOB) suppresses autophagic degradation via over-expressing AKT
pathway and enhances apoptosis in multidrug-resistant SKOV3/TAX
ovarian cancer cells. Biomed Pharmacother. 103:29–37. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hermawan A, Ikawati M, Putri DDP, Fatimah
N and Prasetio HH: Nobiletin inhibits breast cancer stem cell by
regulating the cell cycle: A comprehensive bioinformatics analysis
and in vitro experiments. Nutr Cancer. 76:638–655. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lien LM, Wang MJ, Chen RJ, Chiu HC, Wu JL,
Shen MY, Chou DS, Sheu JR, Lin KH and Lu WJ: Nobiletin, a
polymethoxylated flavone, inhibits glioma cell growth and migration
via arresting cell cycle and suppressing MAPK and Akt pathways.
Phytother Res. 30:214–221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wei D, Zhang G, Zhu Z, Zheng Y, Yan F, Pan
C, Wang Z, Li X, Wang F, Meng P, et al: Nobiletin inhibits cell
viability via the SRC/AKT/STAT3/YY1AP1 pathway in human renal
carcinoma cells. Front Pharmacol. 10:6902019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen PY, Chen YT, Gao WY, Wu MJ and Yen
JH: Nobiletin down-regulates c-KIT gene expression and exerts
antileukemic effects on human acute myeloid leukemia cells. J Agric
Food Chem. 66:13423–13434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wu X, Song M, Gao Z, Sun Y, Wang M, Li F,
Zheng J and Xiao H: Nobiletin and its colonic metabolites suppress
colitis-associated colon carcinogenesis by down-regulating iNOS,
inducing antioxidative enzymes and arresting cell cycle
progression. J Nutr Biochem. 42:17–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jiang H, Chen H, Jin C, Mo J and Wang H:
Nobiletin flavone inhibits the growth and metastasis of human
pancreatic cancer cells via induction of autophagy,
G0/G1 cell cycle arrest and inhibition of
NF-kB signalling pathway. J BUON. 25:1070–1075. 2020.PubMed/NCBI
|
|
54
|
Turdo A, Glaviano A, Pepe G, Calapà F,
Raimondo S, Fiori ME, Carbone D, Basilicata MG, Di Sarno V,
Ostacolo C, et al: Nobiletin and xanthohumol sensitize colorectal
cancer stem cells to standard chemotherapy. Cancers (Basel).
13:39272021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Singh DK, Bose S and Kumar S: Role of
microRNA in regulating cell signaling pathways, cell cycle, and
apoptosis in non-small cell lung cancer. Curr Mol Med. Apr
29–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jahan S, Ansari UA, Srivastava AK,
Aldosari S, Alabdallat NG, Siddiqui AJ, Khan A, Albadrani HM,
Sarkar S, Khan B, et al: A protein-miRNA biomic analysis approach
to explore neuroprotective potential of nobiletin in human neural
progenitor cells (hNPCs). Front Pharmacol. 15:13435692024.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen J, Creed A, Chen AY, Huang H, Li Z,
Rankin GO, Ye X, Xu G and Chen YC: Nobiletin suppresses cell
viability through AKT pathways in PC-3 and DU-145 prostate cancer
cells. BMC Pharmacol Toxicol. 15:592014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu Y, Li Q, Lv LL, Chen JX, Ying HF, Ruan
M, Zhu WH, Xu JY, Zhang CY, Zhang KY, et al: Nobiletin inhibits
breast cancer cell migration and invasion by suppressing the
IL-6-induced ERK-STAT and JNK-c-JUN pathways. Phytomedicine.
110:1546102023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sun Y, Han Y, Song M, Charoensinphon N,
Zheng J, Qiu P, Wu X and Xiao H: Inhibitory effects of nobiletin
and its major metabolites on lung tumorigenesis. Food Funct.
10:7444–7452. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gutiérrez-Venegas G and Rosas-Martínez M:
Nobiletin and 5-demethylnobiletin ameliorate hypopharyngeal
squamous cell carcinoma by suppressing TGF-β-mediated
epithelial-mesenchymal transition. Oncol Lett. 29:1762025.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Allavena G, Debellis D, Marotta R, Joshi
CS, Mysorekar IU and Grimaldi B: A broad-spectrum antibiotic, DCAP,
reduces uropathogenic Escherichia coli infection and enhances
vorinostat anticancer activity by modulating autophagy. Cell Death
Dis. 9:7802018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yamamoto K, Iwadate D, Naito E, Tateishi K
and Fujishiro M: Autophagy as a critical driver of metabolic
adaptation, therapeutic resistance, and immune evasion of cancer.
Curr Opin Biotechnol. 84:1030122023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Niu X, You Q, Hou K, Tian Y, Wei P, Zhu Y,
Gao B, Ashrafizadeh M, Aref AR, Kalbasi A, et al: Autophagy in
cancer development, immune evasion, and drug resistance. Drug
Resist Updat. 78:1011702025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu T, Zhang J, Li K, Deng L and Wang H:
Combination of an autophagy inducer and an autophagy inhibitor: A
smarter strategy emerging in cancer therapy. Front Pharmacol.
11:4082020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Moon JY and Cho SK: Nobiletin induces
protective autophagy accompanied by ER-stress mediated apoptosis in
human gastric cancer SNU-16 cells. Molecules. 21:9142016.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kaneda MM, Messer KS, Ralainirina N, Li H,
Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P,
et al: PI3Kγ is a molecular switch that controls immune
suppression. Nature. 539:437–442. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ashrafizadeh M, Zarrabi A, Saberifar S,
Hashemi F, Hushmandi K, Hashemi F, Moghadam ER, Mohammadinejad R,
Najafi M and Garg M: Nobiletin in cancer therapy: How this plant
derived-natural compound targets various oncogene and
onco-suppressor pathways. Biomedicines. 8:1102020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rosas-Martínez M, González Rosales JA and
Gutiérrez-Venegas G: Nobiletin regulates invasion, migration and
metastasis in hypopharyngeal squamous cell carcinoma. Cell Mol Biol
(Noisy-le-grand). 69:1–6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Miyata Y, Sato T, Yano M and Ito A:
Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal
kinase pathway and inhibition of mitogen-activated
protein/extracellular signal-regulated kinase 1/2 phosphorylation
in antitumor invasive activity induced by the polymethoxy
flavonoid, nobiletin. Mol Cancer Ther. 3:839–847. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu F, Zhang S, Yin M, Guo L, Xu M and
Wang Y: Nobiletin inhibits hypoxia-induced epithelial-mesenchymal
transition in renal cell carcinoma cells. J Cell Biochem.
120:2039–2046. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liu Z, Guo S and Dong Q: Nobiletin
suppresses IL-21/IL-21 receptor-mediated inflammatory response in
MH7A fibroblast-like synoviocytes (FLS): An implication in
rheumatoid arthritis. Eur J Pharmacol. 875:1729392020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Palmulli R, Jackson HK and Edgar JR:
Tethered exosomes containing the matrix metalloproteinase MT1-MMP
contribute to extracellular matrix degradation. J Extracell
Vesicles. 14:e701222025. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Miyata Y, Nagase T, Katsura Y, Takahashi
H, Natsugari H, Oshitari T and Kosano H: In vitro studies on
nobiletin isolated from citrus plants and the bioactive
metabolites, inhibitory action against gelatinase enzymatic
activity and the molecular mechanisms in human retinal Müller cell
line. Biomed Pharmacother. 93:70–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ma Y, Ren X, Patel N, Xu X, Wu P, Liu W,
Zhang K, Goodin S, Li D and Zheng X: Nobiletin, a citrus
polymethoxyflavone, enhances the effects of bicalutamide on
prostate cancer cells via down regulation of NF-κB, STAT3, and ERK
activation. RSC Adv. 10:10254–10262. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Feng SL, Tian Y, Huo S, Qu B, Liu RM, Xu
P, Li YZ and Xie Y: Nobiletin potentiates paclitaxel anticancer
efficacy in A549/T xenograft model: Pharmacokinetic and
pharmacological study. Phytomedicine. 67:1531412020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang Z, Du J, Xu Q, Li Y, Zhou S, Zhao Z,
Mu Y, Zhao AZ, Cao SM and Li F: Resistin promotes nasopharyngeal
carcinoma metastasis through TLR4-mediated activation of p38
MAPK/NF-κB signaling pathway. Cancers (Basel). 14:60032022.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xu Z, Wu D, Fu D, Tang C, Ge J, Zhang Z
and Zhou W: Nobiletin inhibits viability of human renal carcinoma
cells via the JAK2/STAT3 and PI3K/Akt pathway. Cell Mol Biol
(Noisy-le-grand). 66:199–203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shi MD, Liao YC, Shih YW and Tsai LY:
Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways
in HGF-treated liver cancer HepG2 cells. Phytomedicine. 20:743–752.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu J, Wang S, Tian S, He Y, Lou H, Yang
Z, Kong Y and Cao X: Nobiletin inhibits breast cancer via p38
mitogen-activated protein kinase, nuclear transcription factor-κB,
and nuclear factor erythroid 2-related factor 2 pathways in MCF-7
cells. Food Nutr Res. 21:622018.PubMed/NCBI
|
|
80
|
Moon JY, Manh Hung LV, Unno T and Cho SK:
Nobiletin enhances chemosensitivity to adriamycin through
modulation of the Akt/GSK3β/β-Catenin/MYCN/MRP1 signaling pathway
in A549 human non-small-cell lung cancer cells. Nutrients.
10:18292018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Versmissen J, Power JR and Moslehi J:
Vascular medicine and cardio-oncology-A new, evolving clinical
frontier. Vasc Med. 25:205–207. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Andreucci E, Peppicelli S, Ruzzolini J,
Bianchini F and Calorini L: Physicochemical aspects of the tumour
microenvironment as drivers of vasculogenic mimicry. Cancer
Metastasis Rev. 41:935–951. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Folkman J and Klagsbrun M: Angiogenic
factors. Science. 235:442–447. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mehedi F: P-039 - Vascular endothelial
growth factor (VEGF) splice isoforms may hold the key to targeting
tumour angiogenesis in oesophageal cancer. Ann Oncol. 29:v112018.
View Article : Google Scholar
|
|
85
|
Kisacam MA: Nobiletin is capable of
regulating certain anti-cancer pathways in a colon cancer cell
line. Naunyn Schmiedebergs Arch Pharmacol. 396:547–555. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhu F, Wang KB and Rui L: STAT3 activation
and oncogenesis in lymphoma. Cancers (Basel). 12:192019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jiang H, Liu X, Knolhoff BL, Hegde S, Lee
KB, Jiang H, Fields RC, Pachter JA, Lim KH and DeNardo DG:
Development of resistance to FAK inhibition in pancreatic cancer is
linked to stromal depletion. Gut. 69:122–132. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sp N, Kang DY, Joung YH, Park JH, Kim WS,
Lee HK, Song KD, Park YM and Yang YM: Nobiletin inhibits
angiogenesis by regulating Src/FAK/STAT3-mediated signaling through
PXN in ER+ breast cancer cells. Int J Mol Sci.
18:9352017. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Guerrero-Rodríguez SL, Mata-Cruz C,
Pérez-Tapia SM and Velasco-Velázquez MA: Role of CD36 in cancer
progression, stemness, and targeting. Front Cell Dev Biol.
10:10790762022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sp N, Kang DY, Kim DH, Park JH, Lee HG,
Kim HJ, Darvin P, Park YM and Yang YM: Nobiletin inhibits
CD36-dependent tumor angiogenesis, migration, invasion, and sphere
formation through the Cd36/Stat3/Nf-Κb signaling axis. Nutrients.
10:7722018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Deng Y, Tu Y, Yang X, Liao X, Xia Z and
Liao W: Anti-atherosclerosis effect of nobiletin via
PINK1/Parkin-mediated mitophagy and NLRP3 inflammasome signaling
pathway. J Funct Foods. 100:105369–105382. 2023. View Article : Google Scholar
|
|
92
|
Risso V, Lafont E and Le Gallo M:
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and
autoimmune diseases. Cell Death Dis. 13:2482022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yahya SA and Al-Shawi NN: Hepatoprotective
effect of Nobiletin against 5-fluorouracil induce hepatotoxicity.
Curr Res Pharmacol Drug Discov. 7:1001992024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Yang J, Yang Y, Wang L, Jin Q and Pan M:
Nobiletin selectively inhibits oral cancer cell growth by promoting
apoptosis and DNA damage in vitro. Oral Surg Oral Med Oral Pathol
Oral Radiol. 130:419–427. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang M, Liu J, Zhang R, Liang Z, Ding S,
Yu H and Shan Y: Nobiletin, a hexamethoxyflavonoid from citrus
pomace, attenuates G1 cell cycle arrest and apoptosis in
hypoxia-induced human trophoblast cells of JEG-3 and BeWo via
regulating the p53 signaling pathway. Food Nutr Res. 65:2021.
|
|
96
|
Moon JY, Cho M, Ahn KS and Cho SK:
Nobiletin induces apoptosis and potentiates the effects of the
anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric
cancer cells. Nutr Cancer. 65:286–295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lee HJ, Lee EK, Seo YE, Shin YH, Kim HS,
Chun YH, Yoon JS, Kim HH, Han MY, Kim CK, et al: Roles of Bcl-2 and
caspase-9 and −3 in CD30-induced human eosinophil apoptosis. J
Microbiol Immunol Infect. 50:145–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Li N, Zhang Z, Jiang G, Sun H and Yu D:
Nobiletin sensitizes colorectal cancer cells to oxaliplatin by
PI3K/Akt/MTOR pathway. Front Biosci (Landmark Ed). 24:303–312.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Amarsanaa K, Kim HJ, Ko EA, Jo J and Jung
SC: nobiletin exhibits neuroprotective effects against
mitochondrial complex I inhibition via regulating apoptotic
signaling. Exp Neurobiol. 30:73–86. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang R, Chen J, Mao L, Guo Y, Hao Y, Deng
Y, Han X, Li Q, Liao W and Yuan M: Nobiletin triggers reactive
oxygen species-mediated pyroptosis through regulating autophagy in
ovarian cancer cells. J Agric Food Chem. 68:1326–1336. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Chen M, Zhang R, Chen Y, Chen X, Li Y,
Shen J, Yuan M, Chen Y, Wu J and Sun Q: Nobiletin inhibits de novo
FA synthesis to alleviate gastric cancer progression by regulating
endoplasmic reticulum stress. Phytomedicine. 2023:1549022023.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Jeong WJ, Ro EJ and Choi KY: Interaction
between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer
strategy via degradations of β-catenin and RAS by targeting the
Wnt/β-catenin pathway. NPJ Precis Oncol. 2:52018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Borah N, Gunawardana S, Torres H,
McDonnell S and Van Slambrouck S: 5,6,7,3′,4′,5′-Hexamethoxyflavone
inhibits growth of triple-negative breast cancer cells via
suppression of MAPK and Akt signaling pathways and arresting cell
cycle. Int J Oncol. 15:1685–1693. 2017. View Article : Google Scholar
|
|
104
|
Lv K, Zhang L, Zhao H, Ho CT and Li S:
Recent study on the anticancer activity of nobiletin and its
metabolites. J. Food Bioact. 14:53–59. 2021. View Article : Google Scholar
|
|
105
|
Wu X, Song M, Wang M, Zheng J, Gao Z, Xu
F, Zhang G and Xiao H: Chemopreventative effects of nobiletin and
its colonic metabolites on colon carcinogenesis. Mol Nutr Food Res.
59:2383–2394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lai CS, Chang GS, Li S, Lo CY, Ho CT and
Pan MH: Comparison of Anti-proliferative and Anti-inflammatory
Effects of Nobiletin and Its Urinary Metabolite,
3′,4′-Didemethylnobiletin. Nutrition. Functional and Sensory
Properties of Foods, . Ho CT, Mussinan C, Shahidi F and Tratras
Contis E: The Royal Society of Chemistry; pp. 269–280. 2013
|
|
107
|
Su JD, Yen JH, Li S, Weng CY, Lin MH, Ho
CT and Wu MJ: 3′,4′-Didemethylnobiletin induces phase II
detoxification gene expression and modulates PI3K/Akt signaling in
PC12 cells. Free Radic Biol Med. 52:126–141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Devkota HP, Adhikari-Devkota A, Dirar AI
and Belwal T: Chapter 3.1.14 - Nobiletin. In: Naturally Occurring
Chemicals Against Alzheimer's Disease. Belwal T, Nabavi SM, Nabavi
SF, Dehpour AR and Shirooie S: Academic Press; pp. 185–196.
2021
|
|
109
|
Kong JY, Wang CC, Duan XF, et al: Dietary
Antarctic Krill Oil Enhances the Oral Bioavailability of Nobiletin
but Has No Ideal Synergistic Effect on Improving Memory and
Cognition Ability in Aβ1-42 Induced Rats. European Journal of Lipid
Science and Technology. 124:2200049–2200063. 2022. View Article : Google Scholar
|
|
110
|
Ning J, Zheng G, Cai Y, Hu Y, Liu Y, Lai
E, Chen B, Liu Y, Liang Z, Fu J and Wei M: The self-assembly
soluplus nanomicelles of nobiletin in aqueous medium based on solid
dispersion and their increased hepatoprotective effect on
APAP-induced acute liver injury. Int J Nanomedicine. 18:5119–5140.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Hattori T, Tagawa H, Inai M, Kan T, Kimura
SI, Itai S, Mitragotri S and Iwao Y: Transdermal delivery of
nobiletin using ionic liquids. Sci Rep. 9:201912019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Singh AP, Kandpal JB, Sharma RK and Chitme
H: Nobiletin a biologically active phytoconstituent: Systematic
review. J Biol Act Prod Nat. 11:204–211. 2021.
|
|
113
|
Wu X, Song M, Qiu P, Rakariyatham K, Li F,
Gao Z, Cai X, Wang M, Xu F, Zheng J and Xiao H: Synergistic
chemopreventative effects of nobiletin and atorvastatin on colon
carcinogenesis. Carcinogenesis. 38:455–464. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ito H, Negoro H, Kono J, Hayata N, Miura
T, Manabe Y, Miyazaki Y, Mishina M, Woo JT, Sakane N and Okuno H:
Effectiveness and safety of a mixture of nobiletin and tangeretin
in nocturia patients: A Randomized, placebo-controlled,
double-blind, crossover study. J Clin Med. 12:27572023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Koga N, Ohta C, Kato Y, Haraguchi K, Endo
T, Ogawa K, Ohta H and Yano M: In vitro metabolism of nobiletin, a
polymethoxy-flavonoid, by human liver microsomes and cytochrome
P450. Xenobiotica. 41:927–933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sun J, Du K, Huo M, Cao Y, Li J, Zhao F,
Jing W, Sang Y and Tian G: Oligosaccharides, stachyose and
α-dextran, as promising sucrose replacers in pectin gels for
enhanced delivery of nobiletin. Food Chem X. 29:1027802025.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wei R, Zhao S, Feng L, Tian G, Song M,
Zhao C, An Q and Zheng J: Influence of triacylglycerol on the
physical stability and digestion fate of triacylglycerol-bergamot
mixed-oil emulsions with nobiletin. LWT. 144:1112532021. View Article : Google Scholar
|
